PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Clinical trial NCT05922904 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05922904
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-14
- Primary completion
- 2027-10-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.